Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

DOV Pharmaceutical, Inc. is a biopharmaceutical company focused on the development of product candidates for disorders of the central nervous system (CNS). The Company has drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company also has a drug development program subject to regulatory review, Indiplon, which is being developed as a treatment for insomnia. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, Inc. (XTL) for bicifadine, with Blue Note Pharmaceuticals, Inc. (Blue Note) for DOV diltiazem, and with Neurocrine Biosciences, Inc. (Neurocrine) for indiplon.

Pathwork Diagnostics is hoping to offer doctors the ability to predict which diseases a patient may have. The company is developing methods to identify biomarker patterns that indicate certain types of diseases. Many tests cannot identify diseases in their early forms. Pathwork Diagnostics is working on identifying the earliest possible signs of a given disease, such as cancer, to help doctors determine the best therapies to treat that disease. The company was founded in 2002. Investment firms Advent Venture, Prospect Venture, and Versant Ventures are the largest shareholders.

BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.

Haw Par Corporation Limited is engaged in licensing the Tiger trademarks, and owning investments for long-term holding purposes. It has four segments: manufacturing, marketing and trading of Healthcare products; provision of leisure-related services; property rental, and investments in securities. Its healthcare division principally manufactures and distributes analgesic products under the Tiger Balm and Kwan Loong brand. Leisure division provides family and tourist oriented leisure alternatives mainly in the form of oceanariums. Property division owns and leases out several investment properties in the Asia region. Investment division engages in investing activities, mainly in quoted and unquoted securities in Asia region. In December 2009, the Company announced that it completed the dissolution of the subsidiaries Haw Par Realty Private Limited, HPH Property Sdn Bhd, Kwan Loong Industries Sdn Bhd, Haw Par Tiger Balm (Hong Kong) Limited and Kwan Loong Oils (HK) Limited.

The Boehringer Ingelheim group of companies is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the privately–owned company currently has nearly 41,300 employees and 138 affiliated companies spread around the globe. Boehringer Ingelheim is research-driven and dedicated to the discovery, development, manufacture and marketing of innovative human and animal health care products.

New Brunswick Scientific Co. was founded in 1946 and is headquartered in Edison, New Jersey. As of September 24, 2007, New Brunswick Scientific Co. Inc. is a subsidiary of Eppendorf AG. New Brunswick Scientific Co., Inc. and its subsidiaries provide various research equipment and scientific instruments for the life sciences industry. It engages in the design, manufacture, and marketing of equipment that creates, maintains, measures, and controls the physical and biochemical conditions required for the growth, detection, and storage of biological cultures. The company’s products include fermentation equipment, bioreactors, biological shakers, ultra-low temperature freezers, CO2 incubators, nutrient sterilizing and dispensing equipment, tissue culture apparatus, and air samplers. Its products are used in medical, biological, chemical, and environmental research; and for the commercial development of antibiotics, proteins, hormones, enzymes, monoclonal antibodies, agricultural products, fuels, vitamins, vaccines, and other substances. The company sells its equipment to biotechnology and pharmaceutical companies; agricultural and chemical companies; other industrial customers engaged in biotechnology; and medical schools, universities, research institutes, hospitals, and private laboratories; and laboratories of federal, state, and municipal government departments and agencies. It also sells its equipment directly, as well as through scientific equipment dealers to foreign companies, institutions, and governments. The company primarily operates in the United States, Asia, and Europe.

NutraCea is a health science company that has intellectual property that allows the Company to process and convert rice bran into a nutritious ingredient, stabilized rice bran that has applications in various food products and as components of formulations that have applications for treatment modalities in nutritional supplementation. It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both in the United States and internationally. These products include food supplements and medical foods. The Company operates in two segments: the NutraCea segment, which manufactures and distributes ingredients primarily derived from SRB, and the Irgovel segment, which consists of its rice-bran oil and fatted and de-fatted SRB manufacturing subsidiary in Pelotas, Brazil. In November 2009, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankrupt Code.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.